Microbix’s Clot-Buster Drug Project Advances
MISSISSAUGA, Canada, March 14, 2024 (GLOBE NEWSWIRE) — Microbix Biosystems Inc. (TSX:MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that its funding and commercialization partner, Sequel Pharma, LLC (“Sequel”), has executed, with support from Microbix, an agreement with a leading international contract development and manufacturing organization (“CDMO”) for production of the active ingredient (i.e., “Drug Substance”) of Kinlytic® urokinase (“Kinlytic”), a biologic drug for dissolving blood clots.